Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What has changed with riluzole?

V Meininger1, L Lacomblez, F Salachas

  • 1Fédération de Neurologie Mazarin, Division Mazarin, Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital 75013 Paris, France. vincent.meininger@psl.ap-hop-paris.fr

Journal of Neurology
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishing age-stratified reference values for blood Neurofilament Light chain (NfL) using the Lumipulse® platform.

Revue neurologique·2026
Same author

[Proposals from a French expert panel for respiratory care in ALS patients].

Revue des maladies respiratoires·2024
Same author

Quantitative brainstem and spinal MRI in amyotrophic lateral sclerosis: implications for predicting noninvasive ventilation needs.

Journal of neurology·2023
Same author

Proposals from a French expert panel for respiratory care in ALS patients.

Respiratory medicine and research·2022
Same author

Botulinum toxin therapy improves masseter spasticity in Amyotrophic Lateral Sclerosis.

Revue neurologique·2020
Same author

Genetics of amyotrophic lateral sclerosis.

Revue neurologique·2017

Riluzole remains the first standard treatment for amyotrophic lateral sclerosis (ALS), offering hope by slowing disease progression and stimulating research into glutamate

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Neurology

Background:

  • Amyotrophic lateral sclerosis (ALS) treatment landscape before riluzole.
  • Riluzole introduced as the first standard ALS therapy in the early 1990s.
  • Need to assess changes and impact 5 years post-introduction.

Purpose of the Study:

  • Evaluate the impact of riluzole on ALS treatment and research.
  • Review advancements in basic science, clinical activity, and patient care.
  • Assess riluzole's role in fostering collaborative research efforts.

Main Methods:

  • Review of clinical trial data and historical databases.
  • Analysis of basic science research on riluzole's mechanisms.
  • Assessment of patient care and caregiver impact.

Related Experiment Videos

Main Results:

  • Riluzole research stimulated investigation into glutamate's role in ALS.
  • Clinical data supports riluzole's impact on survival rates and muscle strength.
  • Riluzole provided significant hope, slowing disease progression and improving patient outlook.
  • Facilitated national and international collaborations for ALS research and care.

Conclusions:

  • Riluzole continues to be a vital standard treatment for ALS.
  • Further research is needed to optimize administration and explore additional therapeutic mechanisms.
  • Riluzole has fundamentally shifted the paradigm of ALS patient care and research collaboration.